Next Article in Journal
Persistence of Metarhizium brunneum (Ascomycota: Hypocreales) in the Soil Is Affected by Formulation Type as Shown by Strain-Specific DNA Markers
Next Article in Special Issue
Successful Multimodal Therapy with Intracerebral Liposomal Amphotericin B and Systemic High-Dose Isavuconazole in Proven Disseminated Aspergillosis
Previous Article in Journal
The Distinction between Dematiaceous Molds and Non-Dematiaceous Fungi in Clinical and Spiked Samples Treated with Hydrogen Peroxide Using Direct Fluorescence Microscopy
Previous Article in Special Issue
Long-Term Kinetics of Serum Galactomannan during Treatment of Complicated Invasive Pulmonary Aspergillosis
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Dermatophytic Biofilms: Characteristics, Significance and Treatment Approaches

by
Anthi-Marina Markantonatou
*,
Konstantinos Samaras
and
Timoleon-Achilleas Vyzantiadis
Department of Microbiology, Medical School, Aristotle University of Thessaloniki, 541 24 Thessaloniki, Greece
*
Author to whom correspondence should be addressed.
J. Fungi 2023, 9(2), 228; https://doi.org/10.3390/jof9020228
Submission received: 30 November 2022 / Revised: 29 December 2022 / Accepted: 6 February 2023 / Published: 9 February 2023
(This article belongs to the Special Issue Diagnostic and Therapeutic Challenges of Human Fungal Infections)

Abstract

:
Microbes are found in the environment, possibly more often as biofilms than in planktonic forms. Biofilm formation has been described for several important fungal species. The presence of a dermatophytoma in a dermatophytic nail infection was the basis for the proposal that dermatophytes form biofilms as well. This could explain treatment failure and recurrent dermatophytic infections. Several investigators have performed in vitro and ex vivo experiments to study the formation of biofilms by dermatophytes and their properties. The nature of the biofilm structure itself contributes to fungal protection mechanisms against many harmful external agents, including antifungals. Thus, a different approach should be carried out regarding susceptibility testing and treatment. Concerning susceptibility testing, methods to evaluate either the inhibition of biofilm formation, or the ability to eradicate it, have been introduced. As for treatment, in addition to classical antifungal agents, some natural formulations, such as plant extracts or biosurfactants, and alternative approaches, such as photodynamic therapy, have been proposed. Studies that connect the results of the in vitro and ex vivo experimentation with clinical outcomes are required in order to verify the efficacy of these approaches in clinical practice.

1. Introduction

Dermatophytes are pathogens exhibiting tropism for tissues rich in keratin, such as skin, nails and hair. They may affect both humans and animals, and they can also be found in soil where they use decomposing keratinous materials for nutrition. According to the latest taxonomy by De Hoog et al., dermatophytes are currently classified into seven Clades that represent the following seven genera: Trichophyton; Epidermophyton; Nannizzia; Paraphyton; Lophophyton; Microsporum; and Arthroderma [1]. Dermatophytic infections are quite common in the general population and the majority of them are superficial. Their severity varies from mild to quite severe cases. Although they are not life threatening, they may compromise the individual’s quality of life because their symptoms affect physical and, in certain cases, psychological health. Empirical treatment, namely treatment based on prior experience or even without the identification of the pathogen and the performance of susceptibility testing, is common practice. Additionally, in many cases, it seems to be effective. However, there are cases of chronic or recurrent dermatophytoses that require a more specialized approach [2,3]. The application of antifungal susceptibility testing (AFST) could be useful in such cases. Still, dermatophytes’ special characteristics, such as a slow growth rate and poor sporulation, complicate the method and may delay the results. Some investigators have suggested modifications to facilitate the procedure [4,5,6,7], whereas the EUCAST recently published official guidelines for the susceptibility testing of microconidia-forming dermatophytes [8].
Some rational explanations about the persistence of dermatophytic infections and resistance to treatment could be poor compliance to treatment because long-term therapies are often required (even three to twelve months for a nail infection) or pharmacokinetic issues regarding the ability of the drug to reach infected tissues. First, Burkhart et al. in 2002 described a dermatophytoma that could be the cause of resistance to treatment and introduced the idea of dermatophytic biofilms [9]. Biofilms are structures consisting of microbial cells and an extracellular matrix, and they behave in a completely different way than planktonic cells. Bacterial biofilms have been thoroughly studied, as well as those produced by potentially lethal fungal pathogens, such as Candida and Aspergillus spp. Burkhart introduced the suggestion of their existence also in dermatophytic fungal infections.
Subsequently, the aim of this work is to present the current knowledge about dermatophytic biofilms and their properties, as well as the existing approaches of their susceptibility testing and treatment. In order to achieve this, a review of the literature was attempted. The relevant articles were retracted through Pubmed and Scopus, and they concern the time interval from 2001 to present.

2. Biofilms and Dermatophytes

Microbes are found in the environment more as biofilms than in planktonic forms [10,11]. The latter is used to describe free cells suspended in a solvent, whereas biofilms are more complicated structures consisting of large groups of cells and an extracellular matrix (ECM). The formation of biofilms was first observed in bacteria, and it has also been described for several important fungal species, including Candida [12], Cryptococcus [13], Aspergillus [14], Trichosporon [15], Pneumocystis [16] and Coccidioides [17]. In 2002, Burkhart et al. suggested that the formation of a dermatophytoma (a circumscribed fungal mass inside the nail) was an indication that dermatophytes also have the ability to form biofilms [9].
The first step in the biofilm formation procedure is the adhesion of fungal cells on a suitable substrate, which may be either a mucosal or abiotic surface. These cells proliferate, form hyphal structures and subsequently (as the biofilm matures) produce an extracellular matrix which is composed of polysaccharides, lipids, proteins and nucleic acids [18,19]. Fungi, exactly as the other microbes, prefer this kind of growth because it provides them plenty of advantages. Every living organism needs nutrients and protection against external dangers in order to survive, while biofilm structures fulfill both these conditions. In terms of protection, fungal elements enclosed into the biofilm are protected against the action of the host immune system and antifungal agents [20,21,22]. In addition, the extracellular matrix facilitates the diffusion, the use of nutrients and the cooperation between the cells [23,24].
In 2014, Costa-Orlandi et al. first described the characteristics of dermatophytic biofilms according to their in vitro studies on Trichophyton rubrum and Trichophyton mentagrophytes reference strains [25]. Sterilized coverslips were used as abiotic substrates, and after a 3 h pre-adhesion phase, the fungal inoculum was incubated without agitation at 37 °C for 72 h. Subsequently, non-adherent cells were removed, and the morphology was studied by light microscopy. The quantification of the biofilm mass and the extracellular matrix was performed by the use of crystal violet and safranin staining, respectively. The XTT reduction assay was used to determine the metabolic activity, whereas scanning electron microscopy (SEM) and confocal laser-scanning microscopy (CLSM) were used for further studies of the biofilm morphology. These studies confirmed that both species exhibit the ability to form biofilms, but T. rubrum produced a denser mass with higher biomass and extracellular matrix production.
In 2017, Toukabri et al. performed susceptibility studies using clinical isolates from patients with foot mycosis, including 21 T. rubrum and 5 Trichophyton interdigitale, alongside with non-dermatophytic molds [26]. During these studies, all the aforementioned strains exhibited the ability to form biofilms.
In addition to previous in vitro studies, Brilhante et al. performed ex vivo studies on nail fragments to evaluate the biofilm-forming ability of various dermatophytic isolates (T. rubrum, Trichophyton tonsurans, T. mentagrophytes, Microsporum canis and Microsporum gypseum) [27]. The vast majority of them were capable of forming biofilms either in vitro or ex vivo, with the exception of two M. canis strains. Microsporum gypseum, T. rubrum and T. tonsurans were characterized as strong biofilm producers with higher biomass in contrast to T. mentagrophytes and M. canis. The latter seems to produce the weakest biofilms in comparison to the other species. Based on previous studies, the authors assumed that this fact could be explained by differences in cell adhesion [28] and in the type or number of enzymes that different species produce [29]. Another remarkable result was that T. rubrum produced higher biomass ex vivo (on nail fragments) than in vitro. Scanning electron microscopy revealed interesting details about the three-dimensional structure of the biofilms. Those formed in vitro contained hyphae that were grew in several directions, whereas the extracellular matrix filled the area between hyphae. In the ex vivo model, the fungal elements and the extracellular matrix replaced the nail surface in some parts of the nail.
Ex vivo studies have also been performed on animal hair (from cats and dogs) to prove the biofilm-forming ability of M. canis, M. gypseum, T. mentagrophytes and T. tonsurans strains [30]. All the species were able to produce biofilms within a time interval of 14 days, whereas microscopy revealed degradation of the hair shaft, mycelial growth and conidia production, alongside the abundant production of extracellular matrix.

3. Resistance to Antifungals

Antifungal drug resistance is a serious problem regarding the treatment of invasive fungal infections; however, it is also an emerging problem for dermatophytic infections. Dermatophytes try to confront antifungal agents, using several different mechanisms of resistance, such as drug degradation, the overexpression of genes, mutations in targeted genes and multi-drug efflux transporters [31]. Biofilm formation is an additional and very important resistance mechanism.
The nature of the biofilm structure itself contributes to the related microorganisms’ protection mechanisms against any harmful external agent, including antifungals. Studies performed on C. albicans [32] and A. fumigatus [14] (two common fungal pathogens) have demonstrated the important role of the extracellular matrix and persister cells. The extracellular matrix acts as a barrier to antifungal agents, whereas the drug–polysaccharide interaction may affect the effectiveness of the drug [14]. As for persister cells, they are highly tolerant and probably dormant [33] cells that survive from the action of antifungals and have the ability to proliferate when the drug is no longer present in their environment [34]. It has been shown that C. albicans biofilms contain persister cells that are responsible for multi-drug tolerance [32]. Additionally, the upregulation of genes related to multi-drug resistance has been demonstrated for both A. fumigatus and C. albicans [35,36], as well as for genes involved in ergosterol biosynthesis [35,36,37].
Another study on C. albicans demonstrated that the glucan produced is used not only for cell wall formation, but that it is also incorporated into the extracellular matrix and provides the ability to sequestrate the antifungals. Thus, it prevents drugs from reaching their target, resulting in the survival of the fungal cells even at very high exposure levels [38].
As far as dermatophytes are concerned, after Burkhart’s suggestion on the presence of relevant biofilms (dermatophytoma) as a cause of resistance to treatment, many investigators have tried to introduce suitable methods of susceptibility testing in order to also take biofilm formation into account.

4. Susceptibility Testing

The EUCAST recently provided guidelines about antifungal susceptibility testing in dermatophytes [8], whereas the CLSI incorporated to its guidelines instructions about dermatophytic molds several years ago [39]. Both methods are suitable for testing susceptibility to antifungals with regards to dermatophytes in their planktonic form. Bearing in mind all the aforementioned special characteristics of biofilms, it is obvious that there should be a different approach with regards to susceptibility testing and treatment. Concerning susceptibility testing, there have been methods introduced to evaluate either the inhibition of biofilm formation or the ability to eradicate them [26,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56]. Usually, the concentrations able to inhibit or eradicate biofilm structures are much higher than that of common MICs that are measured by assays using planktonic cells [42,50,57].
All the suggested in vitro assays use polystyrene plates and an RPMI 1640 culture medium, while incubation is performed at 37 °C. There is an initial pre-adhesion phase during which the fungal inoculum is transferred into the plates and, after a certain incubation period (usually 3 h), aspiration and washing take place in order to remove any non-adherent cells. Subsequently, antifungal substances are added to the wells and their effect on biofilm formation is evaluated up to 72 h later. To collect information about the effect of antifungals on mature biofilms, the drugs are added after 72 h of incubation and the estimation is conducted 24 h after the addition of them.
Analyses of the biofilms are performed by the use of various techniques and substances. Regarding the in vitro experiments, XTT-tetrazolium salt [40,42,45,46,48,51] and MTT-tetrazolium dye [41,52,53] are used to perform colorimetric techniques that provide indirect indications about the metabolic activity and, subsequently, the viability of the biofilms. Crystal violet [26,43,47,49,50,52,53] and safranin [26,44,54] are also used for colorimetric techniques that yield biomass quantification. Scanning electron microscopy (SEM), confocal laser-scanning microscopy (CLSM) and fluorescence microscopy are used for both in vitro and ex vivo experiments [44,45,46,47,48,49,50,51,52,53,54,55,56], and they provide information about the biofilm structure. The addition of sterile water to the wells with the preformed biofilms, the suspension of their cells and subsequent quantification of the CFUs after inoculation in Sabouraud dextrose agar is a method that is also applied in both in vitro and ex vivo experiments [43,45,48,55]. In all cases, positive and negative controls are used, and all the aforementioned methods are evaluated by comparing the wells under examination with the control wells.
All the aforementioned antibiofilm susceptibility testing studies are summarized in Table 1.

5. Treatment Potentials

The antifungals mostly used to treat dermatophytoses are allylamines, azoles and griseofulvin, either in topical or systemic administration [57]. The susceptibility studies described previously have mainly tested terbinafine, as well as griseofulvin, fluconazole, itraconazole, voriconazole, econazole and ciclopirox additionally. Griseofulvin was also tested in a chloroform solvate, as well as in non-solvated dispersions. Both exhibited a significant reduction in biofilm formation [44]. Recently, Rocha et al. tried an interesting combination of the antidepressant sertraline with the antifungal caspofungin. Their studies demonstrated that there was an excellent synergistic effect [52].
Additionally, some natural formulations were tried, such as plant extracts. Hydroxychavicol (a phenolic component of Piper betle, a plant that usually grows in Southeast Asia) [40], isoflavaspidic acid PB (derived from D. fragrans, a plant species native to tropical Africa) [46] and farnesol (a 15-carbon acyclic sesquiterpene alcohol originally extracted from Farnese acacia tree Vachellia farnesiane) [56] were tested in vitro with favorable results. Hydroxychavicol proved to be effective against dermatophytosis as well, as was demonstrated by studies on an animal model [40]. Additionally, some biosurfactants, such as the sophorolipid produced by Rhodotorula babjevae [47], a rhamnolipid (a biosurfactant which contains rhamnose) produced by Pseudomonas aeruginosa [54], as well as a biosurfactant produced by the entomopathogenic fungus Beauveria bassiana [48], were effective in vitro against dermatophytic biofilms. The sophorolipid was also tested on an in vivo mouse model with favorable results [47], whereas the biosurfactant produced by Beauveria bassiana was effective against ex vivo formed biofilms on healthy hair [48]. Veiga et al. tested propolis ethanol extract, a resin-like material produced by bees, which demonstrated in vitro antifungal activity against planktonic cells, as well as biofilms [43]. The ex vivo study showed good penetration of propolis through the nails, whereas a clinical investigation of 16 patients demonstrated excellent clinical improvement.
Other substances, such as various antidandruff formulations, were also tested [41] and some of them exhibited antibiofilm activity. In 2020, Costa-Orlandi et al. studied the efficacy of the substance nonyl 3, 4-dihydroxybenzoate incorporated into nanostructured lipid systems [55] in order to avoid the toxicity of high concentrations. The formulation proved to be effective against T. rubrum and T. mentagrophytes biofilms. Recently, Brilhante et al. studied the antibiofilm effects of Proteinase K, a broad-spectrum serine protease, and showed that it has antibiofilm properties and a synergistic effect when combined with antifungals [53].
In a review on antibiofilm treatment for onychomycoses, Gupta proposed that biofilms should be disrupted prior to antifungal treatment [2]. In order to achieve this disruption, the components of the extracellular matrix, namely polysaccharides, proteins and extracellular nucleic acids, should be targeted. The enzymes deoxyribonuclease I (DNase I), α-amylase and lyase have been tested, as well as other substances, such as lactic acid, chitosan, terpinen-4-ol-loaded lipid nanoparticles and povidone-iodine (PVP-I) [2]. All the above have been tested in bacterial biofilms and were effective in certain microorganisms [58,59,60,61,62,63,64,65,66]. Specifically for fungal biofilms, DNase demonstrated favorable results in combination with amphotericin B [67] and terpinen-4-ol-loaded lipid nanoparticles were very effective against C. albicans biofilms [68]. As far as dermatophytes are concerned, Brilhante et al. [53] recently explored the inhibitory effect of proteinase K against dermatophytic biofilms and showed that it causes a reduction in mature biofilms. Following biofilm disruption, further techniques in combination with antifungal agents could be applied.
Taraszkievicz et al. proposed the use of photodynamic therapy (PDT) by the use of a LED light source [69], which has also been demonstrated to be effective against C. albicans biofilms [70,71]. Chen et al. showed that PDT seems to make dermatophytic biofilms more susceptible to antifungals [45], whereas Bila et al. tried the substance 2-chalcone (a flavonoid precursor) as a photosensitizer for PDT with favorable results against biofilms formed by T. rubrum and T. mentagrophytes strains [51]. Another interesting alternative approach is that of surface acoustic waves (SAWs), which have been tested and proved to be effective on bacterial biofilms in combination with antibacterial drugs [72].

6. Discussion

Dermatophytic infections, although not life threatening, often cause considerable issues in patients. Sometimes they are difficult to treat or concern recurrent infections. This may happen due to patients’ poor compliance to treatment owing to the regimen’s long duration, the emerging problem of infections by resistant strains or otherwise due to specific patient characteristics (differences in the composition of keratin among individuals that make dermatophytes host specific [73], defects of phagocytes [3], CARD9 deficiency [74] and individuals with a defective skew to Th2 immunity that may exhibit a predisposition to chronic dermatophytic infections [73]). Furthermore, a novel, highly virulent species has emerged. T. indotineae exhibits considerable resistance to terbinafine causing dermatophytic infections that are very difficult to treat, often with large lesions [75]. Biofilm formation also seems to play an important role. Initial information about biofilms was obtained by studies on bacteria and subsequent studies on potentially life-threatening fungal pathogens, such as Candida and Aspergillus. The results of these studies were used to approach dermatophytic biofilms, as well due to their main characteristics (way of formation and basic properties) that are common. The most interesting part is their ability to remain highly resistant to treatment. Two main characteristics that could play an important role are the capturing of the antifungals from the extracellular matrix and the presence of persister cells. Brilhante et al. studied in vitro and ex vivo biofilm formation and noticed that T. rubrum had the ability to produce much higher biomass in comparison with the other analyzed species. They assumed that this amount of biomass represented the development of a hyphal network surrounded by the extracellular matrix and that it could be a rational explanation regarding the difficulty in treating T. rubrum infections [27].
Although several in vitro and ex vivo experiments have demonstrated the formation of dermatophytic biofilms, in vivo visualization has not yet been achieved. Visualization on skin biopsies is not applicable because the structure collapses during the dehydration process [76]. Their definite presence in onychomycoses has also not been proved. However, there are indications, such as the dermatophytes’ in vitro and ex vivo ability to form biofilms, the latter’s firm adherence to the nail plate and their resistance to treatment, that make the presence of dermatophytic biofilms in onychomycoses quite plausible. As for skin infections, scanning electron microscopy has revealed bacterial biofilms in chronic wounds [77]; thus, it could be possible to also have dermatophytic biofilms.
Antifungal susceptibility testing can offer valuable information to optimize treatment. However, classical AFST methods use planktonic suspensions, which do not represent the exact nature of the fungal elements inside the infected lesions. It has been demonstrated that when AFST is performed by the use of biofilm structures, there is up to a 50-fold increase in MICs [42,50]. Given that certain species, such as T. rubrum, have the ability to produce large amounts of biofilm material [25,27], the performance of AFST on biofilms becomes necessary. Several investigators have proposed methods to determine MICs in dermatophytic biofilm formations. Beside the conventional antifungals, natural products have been tested with satisfying results. Plant derivatives, various biosurfactants produced by bacteria or fungi and bee products, such as propolis, have been tested. As it has previously happened, these natural products could be the starting point for the discovery of new drugs that could be effective against dermatophytic biofilms. Additionally, substances already tested and proved to have antifungal properties have been tested in different formulations, such as nonyl 3,4-dihydroxybenzoate, which have been incorporated into a nanostructured lipid system [55]. Recent studies on an antidepressant (sertraline), which proved to act synergistically with the antifungal caspofungin against the dermatophyte T. rubrum, were also interesting [52].
A very interesting approach to treatment is the proposal to act step by step: first to disrupt the biofilm structure, and then to administrate the main antifungal to kill the cells that live inside the structure. Disruption may be accomplished by the use of chemical or natural methods. Chemicals target certain components of the extracellular matrix, whereas natural approaches use light (PDT) or surface acoustic waves (SAWs) to decompose the structure and make the cells inside it vulnerable to classical antifungals. Regarding photodynamic therapy, a natural photosensitizer (the flavonoid precursor 2-chalcone) has shown to be effective against dermatophytes [51]. The advantage of these approaches is that lower dosages of antifungals are required, and thus toxicity and side effects are reduced, as well as the probability of drug resistance [78]. However, these applications do not affect persister cells, which on the other hand could be possibly targeted with certain dosing schemas that would attack them when they try to “wake up” and multiply.
In addition to in vitro studies, many investigators performed ex vivo experiments on human hair and nails as well as on Persian cat hair, to study the dermatophytes’ behavior and their interaction with antifungal substances [48,49,52]. Additionally, in vivo studies were performed on animal models. Ali et al. studied tinea corporis (induced by T. mentagrophytes var. interdigitale) [40] in guinea pigs, whereas Sen et al. used a mouse model of cutaneous dermatophytosis (induced by T. mentagrophytes) to estimate the therapeutic efficiency of the biosurfactant sophorolipid [47]. In 2018, a clinical investigation was performed by Veiga et al. [43]. The study included 16 patients with onychomycosis who were treated with propolis ethanol extract with excellent correspondence.

7. Conclusions

Dermatophytes form biofilms in order to favor their survival. This characteristic is a major reason that makes the treatment of dermatophytic infections in some cases quite difficult. As far as we know, the potential of biofilm formation by the highly virulent T. indotineae species has not yet been explored. Future studies in this field could be very useful in terms of further understanding the infection’s pathophysiology and if biofilm formation is verified for appropriate applications of antibiofilm susceptibility testing. Furthermore, new drugs or even classical antifungals, in combination with novel mechanical methods, could contribute and give a new perspective to the treatment of complicated cases. Additional studies that connect the results of in vitro and ex vivo experiments on dermatophytic biofilms with clinical outcome are required in order to verify the efficacy of all the aforementioned approaches in clinical practice.

Funding

This research received no external funding.

Institutional Review Board Statement

Not applicable. The study concerned a review of the literature.

Informed Consent Statement

Not applicable. The study concerned a review of the literature.

Data Availability Statement

No new data were created or analyzed in this study. Data sharing is not applicable to this article.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. de Hoog, G.S.; Dukik, K.; Monod, M.; Packeu, A.; Stubbe, D.; Hendrickx, M.; Kupsch, C.; Stielow, J.B.; Freeke, J.; Göker, M.; et al. Toward a Novel Multilocus Phylogenetic Taxonomy for the Dermatophytes. Mycopathologia 2017, 182, 5–31. [Google Scholar] [CrossRef] [PubMed]
  2. Gupta, A.K.; Carviel, J.; Shear, N.H. Antibiofilm Treatment for Onychomycosis and Chronic Fungal Infections. Ski. Appendage Disord. 2018, 4, 136–140. [Google Scholar] [CrossRef] [PubMed]
  3. de Sousa Mda, G.; Santana, G.B.; Criado, P.R.; Benard, G. Chronic widespread dermatophytosis due to Trichophyton rubrum: A syndrome associated with a Trichophyton-specific functional defect of phagocytes. Front. Microbiol. 2015, 6, 801. [Google Scholar] [CrossRef] [PubMed]
  4. Schmalreck, A.; Willinger, B.; Czaika, V.; Fegeler, W.; Becker, K.; Blum, G.; Lass-Flörl, C. Susceptibility Screening of Hyphae-Forming Fungi with a New, Easy, and Fast Inoculum Preparation Method. Mycopathologia 2012, 174, 467–474. [Google Scholar] [PubMed]
  5. Czaika, V.A.; Schmalreck, A.F. In vitro susceptibility testing of dermatophytes with their fragmented mycelia as inoculum. J. Adv. Biol. 2014, 6, 775–788. [Google Scholar]
  6. Risslegger, B.; Lass-Flörl, C.; Blum, G.; Lackner, M. Evaluation of a Modified EUCAST Fragmented-Mycelium Inoculum Method for In Vitro Susceptibility Testing of Dermatophytes and the Activity of Novel Antifungal Agent. Antimicrob. Agents Chemother. 2015, 59, 3675–3682. [Google Scholar]
  7. Markantonatou, A.M.; Samaras, K.; Zachrou, E.; Vyzantiadis, T.A. Comparison of Four Methods for the in vitro Susceptibility Testing of Dermatophytes. Front. Microbiol. 2020, 11, 1593. [Google Scholar] [CrossRef]
  8. Arendrup, M.C.; Kahlmeter, G.; Guinea, J.; Meletiadis, J.; Subcommittee on Antifungal Susceptibility Testing (AFST) of the ESCMID European Committee for Antimicrobial Susceptibility Testing (EUCAST). How to: Perform antifungal susceptibility testing of microconidia-forming dermatophytes following the new reference EUCAST method E.Def 11.0, exemplified by Trichophyton. Clin. Microbiol. Infect. 2021, 27, 55–60. [Google Scholar] [CrossRef]
  9. Burkhart, C.N.; Burkhart, C.G.; Gupta, A.K. Dermatophytoma: Recalcitrance to treatment because of existence of fungal biofilm. J. Am. Acad. Dermatol. 2002, 47, 629–631. [Google Scholar] [CrossRef]
  10. Sutherland, I.W. The biofilm matrix—An immobilized but dynamic microbial environment. Trends Microbiol. 2001, 9, 222–227. [Google Scholar] [CrossRef]
  11. Sutherland, I.W. Biofilm exopolysaccharides: A strong and sticky framework. Microbiology 2001, 147 Pt 1, 3–9. [Google Scholar] [CrossRef] [PubMed]
  12. Finkel, J.S.; Mitchell, A.P. Genetic control of Candida albicans biofilm development. Nat. Rev. Microbiol. 2011, 9, 109–118. [Google Scholar] [CrossRef] [PubMed]
  13. Martinez, L.R.; Casadevall, A. Cryptococcus neoformans biofilm formation depends on surface support and carbon source and reduces fungal cell susceptibility to heat, cold, and UV light. Appl. Environ. Microbiol. 2007, 73, 4592–4601. [Google Scholar] [CrossRef]
  14. Beauvais, A.; Muller, F.M. Biofilm formation in Aspergillus fumigatus. In Aspergillus fumigatus and Aspergillosis; Latge, J.P., Steinbach, W.J., Eds.; ASM Press: Washington, DC, USA, 2009; pp. 149–157. [Google Scholar]
  15. Di Bonaventura, G.; Pompilio, A.; Picciani, C.; Iezzi, M.; D’Antonio, D.; Piccolomini, R. Biofilm formation by the emerging fungal pathogen Trichosporon asahii: Development, architecture, and antifungal resistance. Antimicrob. Agents Chemother. 2006, 50, 3269–3276. [Google Scholar] [CrossRef]
  16. Cushion, M.T.; Collins, M.S.; Linke, M.J. Biofilm formation by Pneumocystis spp. Eukaryot. Cell 2009, 8, 197–206. [Google Scholar] [CrossRef]
  17. Davis, L.E.; Cook, G.; Costerton, J.W. Biofilm on ventriculo-peritoneal shunt tubing as a cause of treatment failure in coccidioidal meningitis. Emerg. Infect. Dis. 2002, 8, 376–379. [Google Scholar] [CrossRef] [PubMed]
  18. Azeredo, J.; Azevedo, N.F.; Briandet, R.; Cerca, N.; Coenye, T.; Costa, A.R.; Desvaux, M.; Di Bonaventura, G.; Hébraud, M.; Jaglic, Z.; et al. Critical review on biofilm methods. Crit. Rev. Microbiol. 2017, 43, 313–351. [Google Scholar] [CrossRef]
  19. Percival, S.L.; McCarty, S.M.; Lipsky, B. Biofilms and Wounds: An Overview of the Evidence. Adv. Wound Care 2015, 4, 373–381. [Google Scholar] [CrossRef]
  20. Kravvas, G.; Veitch, D.; Al-Niaimi, F. The increasing relevance of biofilms in common dermatological conditions. J. Dermatol. Treat. 2018, 29, 202–207. [Google Scholar] [CrossRef]
  21. Van Dijck, P.; Sjollema, J.; Cammue, B.P.; Lagrou, K.; Berman, J.; d’Enfert, C.; Andes, D.R.; Arendrup, M.C.; Brakhage, A.A.; Calderone, R.; et al. Methodologies for in vitro and in vivo evaluation of efficacy of antifungal and antibiofilm agents and surface coatings against fungal biofilms. Microb. Cell 2018, 5, 300–326. [Google Scholar] [CrossRef]
  22. Flemming, H.C.; Wingender, J. The biofilm matrix. Nat. Rev. Microbiol. 2010, 8, 623–633. [Google Scholar] [CrossRef] [PubMed]
  23. Ramage, G.; Mowat, E.; Jones, B.; Williams, C.; Lopez-Ribot, J. Our current understanding of fungal biofilms. Crit. Rev. Microbiol. 2009, 35, 340–355. [Google Scholar] [CrossRef] [PubMed]
  24. Kernien, J.F.; Snarr, B.D.; Sheppard, D.C.; Nett, J.E. The Interface between Fungal Biofilms and Innate Immunity. Front. Immunol. 2018, 8, 1968. [Google Scholar] [CrossRef] [PubMed]
  25. Costa-Orlandi, C.B.; Sardi, J.C.; Santos, C.T.; Fusco-Almeida, A.M.; Mendes-Giannini, M.J. In vitro characterization of Trichophyton rubrum and, T. mentagrophytes biofilms. Biofouling 2014, 30, 719–727. [Google Scholar] [CrossRef] [PubMed]
  26. Toukabri, N.; Corpologno, S.; Bougnoux, M.E.; El Euch, D.; Sadfi-Zouaoui, N.; Simonetti, G. In vitro biofilms and antifungal susceptibility of dermatophyte and non-dermatophyte moulds involved in foot mycosis. Mycoses 2018, 61, 79–87. [Google Scholar] [CrossRef] [PubMed]
  27. Brilhante, R.S.N.; Correia, E.E.M.; Guedes, G.M.M.; Pereira, V.S.; Oliveira, J.S.; Bandeira, S.P.; Alencar, L.P.; Andrade, A.R.C.; Castelo-Branco, D.S.C.M.; Cordeiro, R.A.; et al. Quantitative and structural analyses of the in vitro and ex vivo biofilm-forming ability of dermatophytes. J. Med. Microbiol. 2017, 66, 1045–1052. [Google Scholar] [CrossRef]
  28. Baldo, A.; Monod, M.; Mathy, A.; Cambier, L.; Bagut, E.T.; Defaweux, V.; Symoens, F.; Antoine, N.; Mignon, B. Mechanisms of skin adherence and invasion by dermatophytes. Mycoses 2012, 55, 218–223. [Google Scholar] [CrossRef]
  29. Sharifzadeh, A.; Shokri, H.; Khosravi, A.R. In vitro evaluation of antifungal susceptibility and keratinase, elastase, lipase and DNase activities of different dermatophyte species isolated from clinical specimens in Iran. Mycoses 2016, 59, 710–719. [Google Scholar] [CrossRef]
  30. Brilhante, R.S.N.; Aguiar, L.; Sales, J.A.; Araújo, G.D.S.; Pereira, V.S.; Pereira-Neto, W.A.; Pinheiro, A.Q.; Paixão, G.C.; Cordeiro, R.A.; Sidrim, J.J.C.; et al. Ex vivo biofilm-forming ability of dermatophytes using dog and cat hair: An ethically viable approach for an infection model. Biofouling 2019, 35, 392–400. [Google Scholar] [CrossRef]
  31. Martinez-Rossi, N.M.; Peres, N.T.A.; Bitencourt, T.A.; Martins, M.P.; Rossi, A. State-of-the-Art Dermatophyte Infections: Epidemiology Aspects, Pathophysiology, and Resistance Mechanisms. J. Fungi 2021, 7, 629. [Google Scholar] [CrossRef]
  32. LaFleur, M.D.; Kumamoto, C.A.; Lewis, K. Candida albicans biofilms produce antifungal-tolerant persister cells. Antimicrob. Agents Chemother. 2006, 50, 3839–3846. [Google Scholar] [CrossRef] [PubMed]
  33. Lewis, K. Persister cells. Annu. Rev. Microbiol. 2010, 64, 357–372. [Google Scholar] [CrossRef] [PubMed]
  34. Boucherit, Z.; Seksek, O.; Bolard, J. Dormancy of Candida albicans cells in the presence of the polyene antibiotic amphotericin B: Simple demonstration by flow cytometry. Med. Mycol. 2007, 45, 525–533. [Google Scholar] [CrossRef]
  35. Gibbons, J.G.; Beauvais, A.; Beau, R.; McGary, K.L.; Latgé, J.P.; Rokas, A. Global transcriptome changes underlying colony growth in the opportunistic human pathogen Aspergillus fumigatus. Eukaryot. Cell 2012, 11, 68–78. [Google Scholar] [CrossRef]
  36. Nett, J.E.; Lepak, A.J.; Marchillo, K.; Andes, D.R. Time course global gene expression analysis of an in vivo Candida biofilm. J. Infect. Dis. 2009, 200, 307–313. [Google Scholar] [CrossRef]
  37. García-Sánchez, S.; Aubert, S.; Iraqui, I.; Janbon, G.; Ghigo, J.M.; d’Enfert, C. Candida albicans biofilms: A developmental state associated with specific and stable gene expression patterns. Eukaryot. Cell 2004, 3, 536–545. [Google Scholar] [CrossRef] [PubMed]
  38. Nett, J.E.; Sanchez, H.; Cain, M.T.; Andes, D.R. Genetic basis of Candida biofilm resistance due to drug-sequestering matrix glucan. J. Infect. Dis. 2010, 202, 171–175. [Google Scholar] [CrossRef] [PubMed]
  39. CLSI. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi. Approved Standard M38-A2, 2nd ed.; Clinical and Laboratory Standards Institute: Wayne, PA, USA, 2010. [Google Scholar]
  40. Ali, I.; Satti, N.K.; Dutt, P.; Prasad, R.; Khan, I.A. Hydroxychavicol: A phytochemical targeting cutaneous fungal infections. Sci. Rep. 2016, 6, 37867. [Google Scholar] [CrossRef]
  41. dos Santos, R.M.; Dias-Souza, M.V. Effectiveness of five antidandruff cosmetic formulations against planktonic cells and biofilms of dermatophytes. Saudi J. Biol. Sci. 2017, 24, 331–337. [Google Scholar] [CrossRef]
  42. Brilhante, R.S.N.; Correia, E.E.M.; Guedes, G.M.M.; de Oliveira, J.S.; Castelo-Branco, D.S.C.M.; Cordeiro, R.A.; Pinheiro, A.Q.; Chaves, L.J.Q.; Pereira Neto, W.A.; Sidrim, J.J.C.; et al. In vitro activity of azole derivatives and griseofulvin against planktonic and biofilm growth of clinical isolates of dermatophytes. Mycoses 2018, 61, 449–454. [Google Scholar] [CrossRef]
  43. Veiga, F.F.; Gadelha, M.C.; da Silva, M.R.T.; Costa, M.I.; Kischkel, B.; de Castro-Hoshino, L.V.; Sato, F.; Baesso, M.L.; Voidaleski, M.F.; Vasconcellos-Pontello, V.; et al. Propolis Extract for Onychomycosis Topical Treatment: From Bench to Clinic. Front. Microbiol. 2018, 9, 779. [Google Scholar] [CrossRef] [PubMed]
  44. Al-Obaidi, H.; Kowalczyk, R.M.; Kalgudi, R.; Zariwala, M.G. Griseofulvin solvate solid dispersions with synergistic effect against fungal biofilms. Colloids Surf. B Biointerfaces 2019, 184, 110540. [Google Scholar] [CrossRef]
  45. Chen, B.; Sun, Y.; Zhang, J.; Chen, R.; Zhong, X.; Wu, X.; Zheng, L.; Zhao, J. In vitro Evaluation of Photodynamic Effects Against Biofilms of Dermatophytes Involved in Onychomycosis. Front. Microbiol. 2019, 10, 1228. [Google Scholar] [CrossRef]
  46. Lin, H.; Liu, X.; Shen, Z.; Cheng, W.; Zeng, Z.; Chen, Y.; Tang, C.; Jiang, T. The effect of isoflavaspidic acid PB extracted from Dryopteris fragrans (L.) Schott on planktonic and biofilm growth of dermatophytes and the possible mechanism of antibiofilm. J. Ethnopharmacol. 2019, 241, 111956. [Google Scholar] [CrossRef] [PubMed]
  47. Sen, S.; Borah, S.N.; Kandimalla, R.; Bora, A.; Deka, S. Sophorolipid Biosurfactant Can Control Cutaneous Dermatophytosis Caused by Trichophyton mentagrophytes. Front. Microbiol. 2020, 11, 329. [Google Scholar] [CrossRef] [PubMed]
  48. Abdel-Aziz, M.M.; Al-Omar, M.S.; Mohammed, H.A.; Emam, T.M. In Vitro and Ex Vivo Antibiofilm Activity of a Lipopeptide Biosurfactant Produced by the Entomopathogenic Beauveria bassiana Strain against Microsporum canis. Microorganisms 2020, 8, 232. [Google Scholar] [CrossRef]
  49. Castelo-Branco, D.S.C.M.; Aguiar, L.; Araújo, G.D.S.; Lopes, R.G.P.; Sales, J.A.; Pereira-Neto, W.A.; Pinheiro, A.Q.; Paixão, G.C.; Cordeiro, R.A.; Sidrim, J.J.C.; et al. In vitro and ex vivo biofilms of dermatophytes: A new panorama for the study of antifungal drugs. Biofouling 2020, 36, 783–791. [Google Scholar] [CrossRef]
  50. Yazdanpanah, S.; Sasanipoor, F.; Khodadadi, H.; Rezaei-Matehkolaei, A.; Jowkar, F.; Zomorodian, K.; Kharazi, M.; Mohammadi, T.; Nouripour-Sisakht, S.; Nasr, R.; et al. Quantitative analysis of in vitro biofilm formation by clinical isolates of dermatophyte and antibiofilm activity of common antifungal drugs. Int. J. Dermatol. 2023, 62, 120–127. [Google Scholar] [CrossRef]
  51. Bila, N.M.; Costa-Orlandi, C.B.; Vaso, C.O.; Bonatti, J.L.C.; de Assis, L.R.; Regasini, L.O.; Fontana, C.R.; Fusco-Almeida, A.M.; Mendes-Giannini, M.J.S. 2-Hydroxychalcone as a Potent Compound and Photosensitizer Against Dermatophyte Biofilms. Front. Cell. Infect. Microbiol. 2021, 11, 679470. [Google Scholar] [CrossRef]
  52. Rocha, C.H.L.; Rocha, F.M.G.; Bitencourt, T.A.; Martins, M.P.; Sanches, P.R.; Rossi, A.; Martinez-Rossi, N.M. Synergism between the Antidepressant Sertraline and Caspofungin as an Approach to Minimise the Virulence and Resistance in the Dermatophyte Trichophyton rubrum. J. Fungi 2022, 8, 815. [Google Scholar] [CrossRef]
  53. Brilhante, R.S.N.; Lopes, R.G.P.; de Aguiar, L.; de Oliveira, J.S.; Araújo, G.D.S.; Paixão, G.C.; Pereira-Neto, W.A.; Freire, R.S.; Nunes, J.V.S.; de Lima, R.P.; et al. Inhibitory effect of proteinase K against dermatophyte biofilms: An alternative for increasing the antifungal effects of terbinafine and griseofulvin. Biofouling 2022, 38, 286–297. [Google Scholar] [CrossRef] [PubMed]
  54. Sen, S.; Borah, S.N.; Bora, A.; Deka, S. Rhamnolipid exhibits anti-biofilm activity against the dermatophytic fungi Trichophyton rubrum and Trichophyton mentagrophytes. Biotechnol. Rep. 2020, 27, e00516. [Google Scholar] [CrossRef]
  55. Costa-Orlandi, C.B.; Serafim-Pinto, A.; da Silva, P.B.; Bila, N.M.; Bonatti, J.L.C.; Scorzoni, L.; Singulani, J.L.; Dos Santos, C.T.; Nazaré, A.C.; Chorilli, M.; et al. Incorporation of Nonyl 3,4-Dihydroxybenzoate Into Nanostructured Lipid Systems: Effective Alternative for Maintaining Anti-Dermatophytic and Antibiofilm Activities and Reducing Toxicity at High Concentrations. Front. Microbiol. 2020, 11, 1154. [Google Scholar] [CrossRef]
  56. Brilhante, R.S.N.; Paixão, G.C.; Pereira, V.S.; Oliveira, J.S.; Maciel, J.M.; Pereira-Neto, W.A.; Lima-Neto, R.G.; Castelo-Branco, D.S.C.M.; Cordeiro, R.A.; Sidrim, J.J.C.; et al. Atypical chlamydoconidium-producing Trichophyton tonsurans strains from Ceará State, Northeast Brazil: Investigation of taxonomy by phylogenetic analysis and biofilm susceptibility. Microbiology 2021, 167. [Google Scholar] [CrossRef]
  57. Pereira, F.O. A review of recent research on antifungal agents against dermatophyte biofilms. Med. Mycol. 2021, 59, 313–326. [Google Scholar] [CrossRef]
  58. Tetz, G.V.; Artemenko, N.K.; Tetz, V.V. Effect of DNase and antibiotics on biofilm characteristics. Antimicrob. Agents Chemother. 2009, 53, 1204–1209. [Google Scholar] [CrossRef] [PubMed]
  59. Hall-Stoodley, L.; Nistico, L.; Sambanthamoorthy, K.; Dice, B.; Nguyen, D.; Mershon, W.J.; Johnson, C.; Hu, F.Z.; Stoodley, P.; Ehrlich, G.D.; et al. Characterization of biofilm matrix, degradation by DNase treatment and evidence of capsule downregulation in Streptococcus pneumoniae clinical isolates. BMC Microbiol. 2008, 8, 173. [Google Scholar] [CrossRef]
  60. Craigen, B.; Dashiff, A.; Kadouri, D.E. The Use of Commercially Available Alpha-Amylase Compounds to Inhibit and Remove Staphylococcus aureus Biofilms. Open Microbiol. J. 2011, 5, 21–31. [Google Scholar] [CrossRef] [PubMed]
  61. Alkawash, M.A.; Soothill, J.S.; Schiller, N.L. Alginate lyase enhances antibiotic killing of mucoid Pseudomonas aeruginosa in biofilms. APMIS 2006, 114, 131–138. [Google Scholar] [CrossRef]
  62. Kiran, S.; Sharma, P.; Harjai, K.; Capalash, N. Enzymatic quorum quenching increases antibiotic susceptibility of multidrug resistant Pseudomonas aeruginosa. Iran. J. Microbiol. 2011, 3, 1–12. [Google Scholar]
  63. Arias-Moliz, M.T.; Baca, P.; Ordóñez-Becerra, S.; González-Rodríguez, M.P.; Ferrer-Luque, C.M. Eradication of enterococci biofilms by lactic acid alone and combined with chlorhexidine and cetrimide. Med. Oral Patol. Oral Cirugía Bucal 2012, 17, e902–e906. [Google Scholar] [CrossRef]
  64. Chávez de Paz, L.E.; Resin, A.; Howard, K.A.; Sutherland, D.S.; Wejse, P.L. Antimicrobial effect of chitosan nanoparticles on Streptococcus mutans biofilms. Appl. Environ. Microbiol. 2011, 77, 3892–3895. [Google Scholar] [CrossRef] [PubMed]
  65. Orgaz, B.; Lobete, M.M.; Puga, C.H.; San Jose, C. Effectiveness of chitosan against mature biofilms formed by food related bacteria. Int. J. Mol. Sci. 2011, 12, 817–828. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  66. Hosaka, Y.; Saito, A.; Maeda, R.; Fukaya, C.; Morikawa, S.; Makino, A.; Ishihara, K.; Nakagawa, T. Antibacterial activity of povidone-iodine against an artificial biofilm of Porphyromonas gingivalis and Fusobacterium nucleatum. Arch. Oral Biol. 2012, 57, 364–368. [Google Scholar] [CrossRef] [PubMed]
  67. Martins, M.; Henriques, M.; Lopez-Ribot, J.L.; Oliveira, R. Addition of DNase improves the in vitro activity of antifungal drugs against Candida albicans biofilms. Mycoses 2012, 55, 80–85. [Google Scholar] [CrossRef]
  68. Sun, L.M.; Zhang, C.L.; Li, P. Characterization, antibiofilm, and mechanism of action of novel PEG-stabilized lipid nanoparticles loaded with terpinen-4-ol. J. Agric. Food Chem. 2012, 60, 6150–6156. [Google Scholar] [CrossRef] [PubMed]
  69. Taraszkiewicz, A.; Fila, G.; Grinholc, M.; Nakonieczna, J. Innovative strategies to overcome biofilm resistance. Biomed Res. Int. 2013, 2013, 150653. [Google Scholar] [CrossRef]
  70. Junqueira, J.C.; Jorge, A.O.; Barbosa, J.O.; Rossoni, R.D.; Vilela, S.F.; Costa, A.C.; Primo, F.L.; Gonçalves, J.M.; Tedesco, A.C.; Suleiman, J.M. Photodynamic inactivation of biofilms formed by Candida spp., Trichosporon mucoides, and Kodamaea ohmeri by cationic nanoemulsion of zinc 2,9,16,23-tetrakis(phenylthio)-29H, 31H-phthalocyanine (ZnPc). Lasers Med. Sci. 2012, 27, 1205–1212. [Google Scholar] [CrossRef]
  71. Dai, T.; Bil de Arce, V.J.; Tegos, G.P.; Hamblin, M.R. Blue dye and red light, a dynamic combination for prophylaxis and treatment of cutaneous Candida albicans infections in mice. Antimicrob. Agents Chemother. 2011, 55, 5710–5717. [Google Scholar] [CrossRef]
  72. Kopel, M.; Degtyar, E.; Banin, E. Surface acoustic waves increase the susceptibility of Pseudomonas aeruginosa biofilms to antibiotic treatment. Biofouling 2011, 27, 701–710. [Google Scholar] [CrossRef]
  73. Dogra, S.; Uprety, S. The menace of chronic and recurrent dermatophytosis in India: Is the problem deeper than we perceive? Indian Dermatol. Online J. 2016, 7, 73–76. [Google Scholar] [CrossRef] [PubMed]
  74. Lanternier, F.; Pathan, S.; Vincent, Q.B.; Liu, L.; Cypowyj, S.; Prando, C.; Migaud, M.; Taibi, L.; Ammar-Khodja, A.; Stambouli, O.B.; et al. Deep dermatophytosis and inherited CARD9 deficiency. N. Engl. J. Med. 2013, 369, 1704–1714. [Google Scholar] [CrossRef] [PubMed]
  75. Uhrlaß, S.; Verma, S.B.; Gräser, Y.; Rezaei-Matehkolaei, A.; Hatami, M.; Schaller, M.; Nenoff, P. Trichophyton indotineae—An Emerging Pathogen Causing Recalcitrant Dermatophytoses in India and Worldwide—A Multidimensional Perspective. J. Fungi 2022, 8, 757. [Google Scholar] [CrossRef]
  76. Nusbaum, A.G.; Kirsner, R.S.; Charles, C.A. Biofilms in dermatology. Ski. Ther. Lett. 2012, 17, 1–5. [Google Scholar]
  77. James, G.A.; Swogger, E.; Wolcott, R.; Pulcini, E.d.L.; Secor, P.; Sestrich, J.; Costerton, J.W.; Stewart, P.S. Biofilms in chronic wounds. Wound Repair Regen. 2008, 16, 37–44. [Google Scholar] [CrossRef]
  78. Wu, S.; Wang, Y.; Liu, N.; Dong, G.; Sheng, C. Tackling Fungal Resistance by Biofilm Inhibitors. J. Med. Chem. 2017, 60, 2193–2211. [Google Scholar] [CrossRef]
Table 1. Summary of the antibiofilm susceptibility testing studies on dermatophytes, including the dermatophytic strains, methods used and the main conclusions.
Table 1. Summary of the antibiofilm susceptibility testing studies on dermatophytes, including the dermatophytic strains, methods used and the main conclusions.
Study
No.
Ref. No.Author/YearStrainsΑntifungal AgentsMethodsConclusions
1[41]dos Santos et al., 2015T. mentagrophytes
ATCC 9533,
T. rubrum
ATCC 28189
5 antidandruff formulationsMTT viability staining
-
Inhibition of fungal growth, variable efficacy
-
2/5 formulations were effective against mature biofilms
2[40]Ali et al., 2016
-
40 dermatophytic isolates (clinical isolates and 1 reference strain of each species: E. floccosum MTCC 613, M. gypseum MTCC 2819, T. mentagrophytes ATCC 9533, T.rubrum MTCC 296)
-
in vivo studies on guinea pigs (tinea corporis)
Hydroxychavicol (major phenolic component of Piper betle)Biofilm formation quantified by XTT reduction assay
-
All isolates susceptible to hydroxychavicol
-
Inhibitory effect on biofilm formation and reduction in preformed biofilms of T. mentagrophytes reference strain
3[26]Toukabri et al., 2017
-
26 clinical isolates: 21 T. rubrum and 5 T. interdigitale (tinea pedis, onychomycosis)
FLC, ECO, ITR, TRB, GRFBiofilm quantification by crystal violet and safranin redTRB the most effective antifungal against T.rubrum and T. interdigitale
4[42]Brilhante et al., 201823 clinical isolates: 4 T. rubrum, 6 T. tonsurans, 3 T. mentagrophytes, 7 M. canis, 3 M. gypseumITR, VRC, GRF
-
Biofilm biomass quantification by crystal violet
-
XTT assay to estimate the efficacy against mature biofilms
Biofilm cells more tolerant to antifungals than their planktonic forms, in both weak and strong biofilm-forming isolates
5[43]Veiga et al., 2018
-
45 clinical isolates (onychomycosis): 29 T. rubrum, 13 T. mentagrophytes, 2 T. verrucosum, 1 T. interdigitale
-
2 strains (1 T. rubrum, 1 T. interdigitale) for the antibiofilm assays
-
ex vivo studies in nail fragments to evaluate the propolis extract penetration into the nail
-
clinical investigation in 16 patients
Propolis ethanol extract (PE)
-
Quantifying the number of CFUs and biomass
-
Biofilm biomass quantification by crystal violet
-
In vitro antifungal activity in both planktonic cells and preformed biofilms
-
PE able to penetrate through the nail
-
Excellent clinical improvement
6[44]Al-Obaidi et al., 20191 T. rubrum isolateGriseofulvin solvate solid dispersions
-
Biofilm visualization with CLSM
-
Biofilm quantification by safranin staining
-
Metabolic activity by XTT assay
Griseofulvin solvate exhibits significantly higher antifungal activity in comparison to non- solvated form
7[45]Chen et al., 201919 clinical isolates (onychomycosis):
6 T. rubrum, 10 T. mentagrophytes, 3 M. gypseum
TRB, ITR, CPX, FLC alone or in combination with photodynamic treatment
-
Biofilm structures studied with SEM
-
Quantification of biofilm formation and determination of MICs by XTT assay
-
CFU counting
-
Highly efficient photodynamic inhibition/ CFU reduction
-
Biofilms become more susceptible to antifungals after PDT
8[46]Lin et al., 201920 clinical isolates (10 T. rubrum, 6 T. mentagrophytes, 2 M. canis, 2 M. gypseum) and 5 standard strains (2 T. rubrum, 1 T. mentagrophytes, 1 M. canis, 1 M. gypseum)
-
Isoflavaspidic acid PB (extracted from D. fragrans)
-
AmpB, TRB as reference antifungal agents
-
XTT assay for effects on biofilm formation and on preformed biofilms
-
SEM for the morphology of mature biofilms
-
Biomass analyzed by gravimetric analysis
-
Extracellular exopolysaccharide quantification with anthranone sulfuric acid method
-
Ergosterol content of T. rubrum mature biofilms by UPLC
-
All isolates effectively inhibited
-
TRB the most effective antifungal agent
-
Isoflavaspidic acid PB can inhibit biofilm formation; destroy pre-mature biofilms; and
decrease biofilm biomass, biofilm extracellular exopolysaccharide and ergosterol content
9[47]Sen et al., 2020
-
1 T. mentagrophytes strain
-
in vivo studies in a mouse model
-
Sophorolipid produced by Rhodotorula babjevae
-
TRB as a standard drug
-
Mycelia studied by SEM
-
Mycelial topography (visualization of the effect) by AFM and CLSM
-
Effective against planktonic forms and biofilms
-
In vivo therapeutic efficiency
10[48]Abdel-Aziz et al., 2020
-
M. canis ATCC 36299
-
ex vivo on healthy hair
A biosurfactant produced by Beauveria bassiana (BBLP)
-
XTT assay to measure the inhibitory effects on biofilms
-
ex vivo biofilms were visualized using stereo microscopy, SEM and FM
-
CFU counting
-
Mycelial growth of M. canis significantly inhibited
-
The biofilm eradication percentage increased when increasing the BBLP concentration
-
Effective against ex vivo biofilms
11[49]Castelo-Branco et al., 2020
-
18 dermatophytic strains (12 M. canis, 6 T. mentagrophytes)
-
ex vivo model on Persian cat hair
GRF, ITR, TRB
-
Biofilm biomass quantification by crystal violet
-
Metabolic activity by XTT reduction assay
-
SEM and CLSM for the evaluation of the ex vivo biofilm susceptibility testing
-
Dermatophytic biofilms grown in vitro are more tolerant to antifungals (higher MICs) in comparison to planktonic growth
-
Dermatophytic biofilms grown ex vivo are more tolerant to antifungals than those grown in vitro
12[54]Sen et al., 20201 T. rubrum,
1 T. mentagrophytes
rhamnolipid (RL-SS14) produced by Pseudomonas aeruginosa
-
Crystal violet staining
-
ECM quantification by safranin staining
-
Biofilm dispersal ability estimated by crystal violet and safranin staining
-
Biofilm imaging by SEM, CLSM and AFM
-
Inhibitory and disruptive effects on biofilms
13[55]Costa-Orlandi et al., 2020T. rubrum ATCC 28189,
T. rubrum ATCC MYA-4438 and T. mentagrophytes
ATCC 11481
Nonyl
3,4-dihydroxybenzoate incorporated into a
nanostructured lipid system
-
Metabolic activity estimated by XTT reduction assay
-
Topographical characteristics analyzed by SEM
-
CFU counting
-
The incorporation into the lipid system maintains its effectiveness against both planktonic cells and biofilms
14[56]Brilhante 2021Chlamydoconidium-producing Trichophyton tonsurans strainsTRB and farnesol
-
Analysis of metabolic activity
-
Quantification of biomass
-
Observation by SEM
-
Both TRB and farnesol reduced biomass and metabolic activity of mature biofilms (64.4–69%)
15[51]Bila et al., 2021T. rubrum ATCC 28189, T. rubrum ATCC MYA-4438, T.mentagrophytes ATCC 114812-chalcone (flavonoid precursor),
TRB, FLC
-
Metabolic activity by XTT reduction assay
-
Biofilms’ topographic analysis by SEM
-
Evaluation of cell damage by CLSM
-
2-chalcone: anti-dermatophytic and antibiofilm properties
-
2-chalcone’s use as a photosensitizer for PDT is effective against dermatophytes
16[52]Rocha et al., 2022
-
1 T. rubrum strain
-
ex vivo study (human nail infection assay)
Sertraline with or without caspofungin
-
Metabolic activity by MTT assay
-
Biofilm quantification by crystal violet
-
Visualization by SEM
-
Excellent synergistic effects (in vitro inhibition of T. rubrum)
-
Low concentrations of sertraline are effective against T. rubrum biofilms if combined with caspofungin
17[53]Brilhante et al., 202214 dermatophytic strains: (3 M. canis, 5 T. tonsurans, 4 T. mentagrophytes,
1 T. rubrum, 1 E. floccosum)
Proteinase K, TRB, GRF
-
Biofilm biomass quantification by crystal violet
-
Biofilm metabolic activity by MTT
-
Visualization by CLSM+ Live/Dead fluorescent dye (SYTO9/propidium iodide) and SEM
-
Proteinase K causes a reduction in the mature biofilms
-
Synergistic effect against mature biofilms when combined with antifungals
18[50]Yazdanpanah et al., 202250 clinical isolates of nail, skin and hair infections:
14 T. mentagrophytes; 13 T. rubrum; 4 T. interdigitale; 2 T. tonsurans; 2 T. verrucosum; 1 T. persicum; 1 T. simii; 6 M. canis; 3 E. floccosum; 1 Nannizzia gypsea; 3 unknown
TRB, GRF, ITR
-
Biofilm quantification by crystal violet
-
Visualization of the ECM by optical microscopy
-
Visualization of
the biofilms’ three-dimensional structure by SEM
-
A high percentage (74%) of the clinical isolates were capable to form biofilms in vitro
-
TRB had excellent inhibitory activity against biofilm formation
-
Concentration needed for 80% prevention of the biofilm formation was up to eightfold of the TRB MIC
FLC: fluconazole; ECO: econazole; ITR: itraconazole; TRB: terbinafine; GRF: griseofulvin; VRC: voriconazole; CPX: ciclopirox; AmpB: amphotericin B; CLSM: confocal laser-scanning microscopy; SEM: scanning electron microscopy; AFM: atomic force microscopy; FM: fluorescence microscopy; UPLC: ultra-performance liquid chromatography; ECM: extracellular matrix, PDT: photodynamic therapy, CFUs: colony-forming units.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Markantonatou, A.-M.; Samaras, K.; Vyzantiadis, T.-A. Dermatophytic Biofilms: Characteristics, Significance and Treatment Approaches. J. Fungi 2023, 9, 228. https://doi.org/10.3390/jof9020228

AMA Style

Markantonatou A-M, Samaras K, Vyzantiadis T-A. Dermatophytic Biofilms: Characteristics, Significance and Treatment Approaches. Journal of Fungi. 2023; 9(2):228. https://doi.org/10.3390/jof9020228

Chicago/Turabian Style

Markantonatou, Anthi-Marina, Konstantinos Samaras, and Timoleon-Achilleas Vyzantiadis. 2023. "Dermatophytic Biofilms: Characteristics, Significance and Treatment Approaches" Journal of Fungi 9, no. 2: 228. https://doi.org/10.3390/jof9020228

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop